| abstract |
Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a FcϜRIIA polymorphism, or a FcϜRIIIA polymorphism, or both an FcϜRIIA polymorphism and a FcϜRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcϜRIIA polymorphism, or FcϜRIIIA polymorphism, or both the FcϜRIIA polymorphism and the FcϜRIIIA polymorphism. |